Quantcast

Early-Stage Minimally-Invasive Biomarkers in Alzheimer’s Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014

September 1, 2014

DUBLIN, Sept. 1, 2014 /PRNewswire/ – Research and Markets has announced the addition of the ” Early-Stage Minimally-Invasive Biomarkers in Alzheimer’s Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014″ report to their offering.

http://photos.prnewswire.com/prnvar/20130307/600769

This report is a comprehensive analysis and market study of new developments relating to early-stage minimally-invasive biomarkers in Alzheimer’s disease, which have been ‘functionally reviewed’ alongside existing AD drugs and candidates in the AD drug pipeline, and applicable commercial AD diagnostics.

New advances have been made in the discovery and validation of biomarkers in Alzheimer’s disease (AD), offering much-needed opportunities to accelerate disease research, drug discovery and the development of low-cost minimally-invasive tests that will be available to much wider patient populations.

This report gives a comprehensive and up-to-date analysis of new findings relating to the discovery and clinical evaluation of AD-related biomarkers with potential to allow early detection or progression of this disease, based on minimally-invasive or non-invasive methods. With a focus on controlled human studies of AD, these biomarker findings are ‘functionally reviewed’ alongside drugs and drug candidates in the development pipeline, and a market analysis of applicable (minimally-invasive) AD-related diagnostics tests, platforms and developments. This report also includes an analysis of related opportunities in AD research, drug discovery, clinical trials and clinical diagnostics.

Key Topics Covered:

Executive Summary

Chapter 1. Background

Chapter 2. Blood Biomarkers

Chapter 3. Autoantibodies

Chapter 4. Urinary Biomarkers

Chapter 5. Salivary Biomarkers

Chapter 6. Other Biomarkers

Chapter 7. AD Drug Pipeline

Chapter 8. Diagnostics Companies of Minimally-Invasive AD Diagnostics

Chapter 9. An Integrated Analysis of AD Biomarkers

Chapter 10. Conclusions and Opportunities

For more information visit http://www.researchandmarkets.com/research/mh4stv/_earlystage

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets


Source: PR Newswire



comments powered by Disqus